Kiniksa Pharmaceuticals International Plc [KNSA] stock is trading at $20.76, up 3.64%. One of the good ways to gauge the recent performance is if the stock’s short-term value is rising or falling. The KNSA shares have gain 11.97% over the last week, with a monthly amount glided 2.52%, and seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Kiniksa Pharmaceuticals International Plc [NASDAQ: KNSA] stock has seen the most recent analyst activity on September 13, 2024, when Jefferies initiated its Buy rating and assigned the stock a price target of $40. Previously, Wells Fargo started tracking the stock with Overweight rating on May 03, 2024, and set its price target to $34. On June 29, 2020, BofA Securities reiterated its Buy rating and revised its price target to $40 on the stock. BofA/Merrill started tracking the stock assigning a Buy rating and suggested a price target of $25 on April 01, 2020. Barclays initiated its recommendation with a Overweight and recommended $26 as its price target on March 11, 2019. Wedbush reiterated a Outperform rating for this stock on December 12, 2018, and upped its price target to $33. In a note dated June 19, 2018, JMP Securities initiated an Mkt Outperform rating and provided a target price of $33 on this stock.
Kiniksa Pharmaceuticals International Plc [KNSA] stock has fluctuated between $16.56 and $28.15 over the past year. Currently, Wall Street analysts expect the stock to reach $37.5 within the next 12 months. Kiniksa Pharmaceuticals International Plc [NASDAQ: KNSA] shares were valued at $20.76 at the most recent close of the market. An investor can expect a potential return of 80.64% based on the average KNSA price forecast.
Analyzing the KNSA fundamentals
Kiniksa Pharmaceuticals International Plc [NASDAQ:KNSA] reported sales of 384.10M for the trailing twelve months, which represents a growth of 67.37%. Gross Profit Margin for this corporation currently stands at 0.61% with Operating Profit Margin at -0.07%, Pretax Profit Margin comes in at -0.04%, and Net Profit Margin reading is -0.02%. To continue investigating profitability, this company’s Return on Assets is posted at -0.02, Equity is -0.02 and Total Capital is -0.06. An extended analysis of the company’s primary financial structure reveals a debt-to-equity ratio of0.02.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 19.96 points at the first support level, and at 19.16 for the second support level. However, for the 1st resistance point, the stock is sitting at 21.17, and for the 2nd resistance point, it is at 21.58.
Ratios To Look Out For
For context, Kiniksa Pharmaceuticals International Plc’s Current Ratio is 3.24. Also, the Quick Ratio is 2.95, while the Cash Ratio stands at 1.01. Considering the valuation of this stock, the price to sales ratio is 3.90, the price to book ratio is 3.43.
Transactions by insiders
Recent insider trading involved Tessari Eben, CHIEF OPERATING OFFICER, that happened on Jan 13 ’25 when 14000.0 shares were sold. Officer, Tessari Eben completed a deal on Jan 13 ’25 to buy 14000.0 shares. Meanwhile, CHIEF OPERATING OFFICER Tessari Eben sold 23017.0 shares on Dec 16 ’24.